ClinicalTrials.gg
CompletedNCT06624059HORIZON 2Updated Aug 19, 2026

A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of Alectinib and Cisplatin in Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 11 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing alectinib in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 14 under way, 4 of them phase 3. alectinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
25th of 27
11 · median 90
Started
2024
with 1 other
Phase 3
7 of 27
none open now
Registered
24th of 27
by date
Lead sponsor
12 of 27
Hoffmann-La Roche

Among the 27 studies testing alectinib in Carcinoma, Non-Small-Cell Lung, this one is the 25th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 3, and was the 24th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 27 studies testing alectinib in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About alectinib

alectinib: first FDA approval 2015 (ALECENSA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing alectinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The objective of this study is to explore the safety of alectinib in combination with chemotherapy in participants with resectable NSCLC. Cohort B1 is a phase II cohort that will assess the safety of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Complete resection of the primary NSCLC with negative margins
  • Confirmed stage II to select stage IIIB (T3N2) NSCLC of non-squamous (adenocarcinoma) histology
  • (ECOG) performance status of 0 or 1
  • Documented ALK fusion

Exclusion criteria

Exclusion Criteria:

  • NSCLC of squamous or mixed histology regardless of the presence of an ALK mutation
  • Prior exposure to any systemic anti-cancer therapy
  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Cohort B1

    Participants will receive alectinib in combination with a platinum-based chemotherapy for up to 4 cycles (cycle length = 3 weeks), followed by alectinib monotherapy for up to 2 years.

    Drug: Alectinib · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed

Interventions

  • Participants will receive oral alectinib twice daily (BID) for up to 2 years.

  • Participants will receive intravenous (IV) cisplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).

  • Participants will receive IV carboplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).

  • Participants will receive IV pemetrexed on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).

06

What researchers measure

Primary outcomes

  1. Incidence, Type, and Severity of Adverse Events (AEs) With Onset up to 28 Days After the Last Dose of Chemotherapy

    Time frame: Up to 28 days after the last dose of chemotherapy treatment (up to 4 cycles, cycle length = 3 weeks)

Secondary outcomes

  1. Incidence, Type, and Severity of AEs With Onset up to 28 Days After the Last Dose of Study Treatment or Until Last on Site/Discontinuation Visit, Whichever Comes First

    Time frame: From first dose to up to approximately 2 years

07

Study locations

11 sites
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Instituto do Cancer do Estado de Sao Paulo - ICESP
    São Paulo, São Paulo 01246-000, Brazil
  • RedSalud Vitacura
    Santiago, Chile
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • The third people's hospital of Chengdu
    Chengdu, China
  • Guangdong General Hospital
    Guangzhou, 510000, China
  • Jinhua municipal central hospital
    Jinhua, China
  • Yunnan Cancer Hospital
    Kunming, 650118, China
  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
    Perugia, Umbria 06156, Italy
  • Asan Medical Center
    Seoul, 05505, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jul 2026, 20 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 20 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 2, 2024
StartActual
Nov 18, 2024
Primary completionActual
Jul 31, 2026
CompletionActual
Jul 31, 2026
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06624059
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 2, 2024
Start date
Nov 18, 2024
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026
Last update
Aug 19, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alectinib · Cisplatin · Carboplatin · Pemetrexed

Start the discussion